Radiance Biopharma has entered an agreement potentially worth up to $1.165 billion for global rights to a bispecific nanobody antibody-drug conjugate (ADC) developed by Novatim Immune Therapeutics. The ADC targets c-MET and EGFR receptors and aims to treat solid tumors, currently advancing through Phase I trials in China with FDA clearance for U.S. trials. The deal includes significant milestone payments and royalties and excludes certain Asian territories retained by Novatim. This acquisition positions Radiance at the forefront of bispecific ADC development in oncology, an emerging modality showing promise to improve targeted cancer therapies.